Profiles people listing in a scrolling container.
  1. Home
  2. Faculty

Stanley Perlman, MD, PhD

Professor of Microbiology and Immunology

Introduction

My laboratory has been interested in the pathogenesis of murine coronavirus infections for several years. Now, we also study three respiratory human coronavirus infections: SARS (Severe Acute Respiratory Syndrome)-coronavirus, Middle East Respiratory syndrome (MERS)-coronavirus, SARS-CoV-2 (COVID-19), human coronavirus-OC43, and human coronavirus-NL63.

Mice infected with mouse hepatitis virus develop a demyelinating disease with many similarities to the human disease, multiple sclerosis. Research in my laboratory is aimed at determining the immunological and viral factors involved in the demyelinating process. Previously, we determined the CD4 and CD8 T cell epitopes recognized in the central nervous system (CNS) of infected mice. We showed that in mice infected chronically with the virus, cytotoxic T cell escape mutants arise. These mutations completely abrogate recognition by CD8 T cells and thereby facilitate persistence.

We have developed reverse genetics system for introducing mutations into the murine coronavirus, SARS-CoV, SARS-CoV-2, and MERS-CoV genomes. We also study the anti-inflammatory components that are needed to diminish immunopathological disease, with specific focus on regulatory CD4 T cells and IL-10. The ultimate goal of our work is to understand the interplay of pro and anti-inflammatory factors that result in myelin and lung destruction.

SARS-CoV, SARS-CoV-2, and MERS-CoV cause the most significant diseases of any of the human coronaviruses. The diseases are especially severe in aged populations. We are using mice infected with murine adapted strains of SARS-CoV and SARS-CoV-2 to understand the basis of these severe diseases. We also study the coronavirus that causes the Middle East Respiratory Syndrome (MERS-CoV). We have developed mouse models for studying MERS and evaluate several MERS-CoV specific vaccines and therapies. We also study immune responses in patients who survived MERS, in collaboration with investigators from the Kingdom of Saudi Arabia and from China. We have developed several mouse models for COVID-19 We are studying anosima, commonly found in COVID-19 patients and survivors.

Current Positions

  • Professor of Microbiology and Immunology
  • Professor of Pediatrics
  • University of Iowa Distinguished Chair

Education

  • AB in Physics, University of Rochester, Rochester, New York
  • PhD in Biophysics, Massachusetts Institute of Technology, Cambridge, Massachusetts
  • MD in Medicine, University of Miami School of Medicine, Miami, Florida
  • Fellow, Massachusetts Institute of Technology, Cambridge, Massachusetts
  • Fellow, Harvard University, Cambridge, Massachusetts
  • Fellow, University of Edinburgh, Edinburgh, Scotland
  • Fellow, Brandeis University, Waltham, Massachusetts
  • Resident, Children's Hospital Medical Center, Boston, Massachusetts
  • Fellow in Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts

Graduate Program Affiliations

Center, Program and Institute Affiliations

Research Interests

  • Infectious Diseases
  • RNA virus pathogenesis
  • SARS-CoV biology and pathogenesis
  • Virus-induced demyelination

Licenses & Certifications

  • Medical License, Iowa, Renewal Date: 6/1/2026
  • American Board of Pediatrics
  • Medical License, Massachusetts

Selected Publications

  • Patel RB, Jha AB, Verma AK, Jain A, Saini S, Muia J, Gurung P, Perlman S, Budnik I, Chauhan A. (2025). Imbalanced VWF-ADAMTS13 axis contributes to the detrimental impact of a preceding respiratory tract infection on stroke. Blood Adv. 2025 Jan:bloodadvances. 2024014622.
  • Zheng J, Dhakal H, Qing E, Shrestha R, Geller AE, Morrissey SM, Saxena D, Hu X, Li H, Li H, Wilhelmsen K, Wendt LH, Klumpp K, Hume PS, Janssen WJ, Brody R, Palmer KE, Uriarte SM, Ten Eyck PP, Meyerholz DK, Merchant ML, McLeish K, Gallagher T, Huang J, Yan J, Perlman S. (2025). CXCL12 ameliorates neutrophilia and disease severity in SARS-CoV-2 infection. J. Clin Invest. 2025 Jan 7:e188222.  doi: 10.1172/JCI188222. PMCID
  • Hassan AM, Mühlemann B, Al-Subhi TL, Rodon J, El-Kafrawy SA, Memish Z, Melchert J, Bleicker T, Mauno T, Perlman S, Zumla A, Jones TC, Müller MA, Corman VM, Drosten C, Azhar EI. (2025). Ongoing Evolution of Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, 2023-2024. Emerg Inf Dis 31:57-65. PMCID:PMC11682817
  • Odle A, Kar M, Verma AK, Sariol A, Meyerholz DK, Suthar MS, Wong LR, Perlman S. (2024). Tissue resident memory T cells contribute to protection against heterologous SARS-CoV-2 challenge. JCI Insight 9:e184074. PMCID: PMC11623939.
  • Perlman S, Sariol A. (2024). Pathogenic T cells in post-viral lung disease in mice. Nat Immunol. 25(11):1991-1992.
  • Ye G, Bu F, Pan R, Mendoza A, Yang G, Spiller B, Wadzinski BE, Du L, Perlman S, Liu B, Li F.(2024) Dual-role epitope on SARS-CoV-2 spike enhances and neutralizes viral entry across different variants. PLoS Pathog. 20(9):e1012493. PMCID: PMC11407660.
  • Ye G, Bu F, Pan R, Mendoza A, Saxena D, Zheng J, Perlman S, Liu B, Li F. (2024). Structure-guided in vitro evolution of nanobodies targeting new viral variants. PLoS Pathog. 20: e1012600. PMCID: PMC11460708.
  • Wang G, Verma AK, Guan X, Bu F, Odle AE, Li F, Liu B, Perlman S, Du L. (2024) Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge. J.Virol. 98(9):e0037624. PMCID: PMC11449030
  • Lowery SA, Schuster N, Wong L-YR, Carrillo T Jr, Peters E, Odle A, Sariol A, Cesarz I, Li P, Perlman S. (2024). Mouse hepatitis virus JHMV I protein is required for maximal virulence. J. Virol. 98(9):e0068024. PMCID: PMC11406938.
  • Zhang W, Shi K, Hsueh FC, Mendoza A, Ye G, Huang L, Perlman S, Aihara H, Li F. (2024). Structural basis for mouse receptor recognition by bat SARS2-like coronaviruses. Proc Natl Acad Sci. 121:e2322600121. PMCID: PMC11317568.